Recent News

Innovascreen publishes study featuring new real-time ASET platform assay

Nova Scotia, April 10, 2012 – While there are many new and exciting cancer drugs under development around the world, their ability to target and then penetrate a patient’s tumor is critical for their success in the clinic. But what if one could use real-time imaging to watch a drug as it leaks into a tumor? A team of researchers led by Innovascreen’s Dr. John Lewis have developed a new method that does just this, by watching the accumulation of drug in human tumors implanted in chicken embryos using a new application of their ASET platform. Their findings appear in an article entitled “Real-Time Visualization and Quantitation of Vascular Permeability In Vivo: Implications for Drug Delivery”, published in the journal PLoS ONE.

Read the entire release Download PDF

ASET platform used in new study to switch therapeutic targets ON and OFF

Nova Scotia, February 15, 2012 – Innovascreen, Inc. announces today the publication of an exciting study using the ASET Platform in the journal, PLoS ONE. The paper, entitled "Imaging the Impact of Chemically Inducible Proteins on Cellular Dynamics In Vivo,” describes a novel approach to monitor protein activity within cancer cells in vivo, follow the impact in real time, and determine the consequences.

Read the entire release Download PDF

Metastasis study using ASET platform featured on the cover of Laboratory Investigation

Nova Scotia, July 28, 2011 – Innovascreen, Inc. announces today that work done using the ASET Platform was featured on the cover of a leading journal, Laboratory Investigation. The paper, entitled "Nuclear Localization of Maspin is Essential for its Inhibition of Tumor Growth and Metastasis,” demonstrates that the cellular protein, maspin, acts as a potent suppressor of tumor growth and spread, but only when it is able to penetrate the nucleus.

Read the entire release Download PDF

Tumor-targeted nanoparticles evaluated using ASET platform featured on the cover of Small Journal

Nova Scotia, June 27, 2011 – Innovascreen, Inc. announces today that the study entitled "Intravital imaging of human prostate cancer using bombesin-targeted viral nanoparticles" by Dr. John Lewis using the ASET Platform was featured on the cover of this month’s issue of the industry leading journal, Small.

Read the entire release Download PDF

Innovascreen secures patent covering Fusogenix intracellular delivery platform

Nova Scotia, January 10, 2011 – Innovascreen, Inc. announces today the U.S. Patent Office issued United States Patent #7,851,595 to Innovascreen for novel fusogenic proteins and their uses. These fusogenic proteins are a key component of Innovascreen's intracellular drug delivery platform, Fusogenix.

Read the entire release

Innovascreen Partners with UWO to Advance Novel Therapeutics

Nova Scotia, November 17, 2010 – Innovascreen announces today that it has entered into an Agreement with WORLDiscoveries at The University of Western Ontario (UWO) to advance novel therapeutics for the treatment of spinal cord injury. The partnership will build on the groundbreaking work done by Dr. Arthur Brown in the Department of Anatomy and Cell Biology.

Read the entire release

Innovascreen to Collaborate with the NCI to Evaluate Novel Anti-angiogenic Agents

Nova Scotia, October 14, 2010 – Innovascreen announces today that it has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the US National Institute of Health to evaluate a panel of compounds for anti-angiogenic activity using its proprietary in vivo angiogenesis assay.

Read the entire release

Innovascreen and Saint Mary's University Partner to Advance Novel Brain Cancer Therapeutics

Nova Scotia, February 17, 2010 – Innovascreen announces today an agreement with Saint Mary’s University to option the rights to a library of novel dacarbazine analogs, a promising class of alkylating agents similar to temozolomide, a first line therapy for an aggressive type of brain tumour known as glioblastoma.

Read the entire release

Innovascreen launches new website

Nova Scotia, February 1, 2010 – Innovascreen announces today the launch of a new website as the first step in a re-development of corporate strategy.

Read the entire release

Innovascreen appoints new Director, Business Development

Nova Scotia, November 1, 2009 – Innovascreen announced today the hiring of Mr. Jeffrey Skinner as Director of Business Development. In this role, Jeff will be responsible for all negotiation and partnerships as well as lead Innovascreen’s efforts to raise money in 2010.

Read the entire release

Innovascreen announces ACOA funding

Nova Scotia, October 11, 2009 – Innovascreen announces today the approval of $287,400 from the Atlantic Canada Opportunities Agency. The funds under this grant will be used to develop an innovative drug delivery system.

Read the entire release

Innovascreen announces funding from IRAP for Fusogenix platform development

Nova Scotia, May 6, 2009 – Innovascreen announces today further funding of $343,200 under the National Research Council of Canada’s Industrial Research Assistance Program. The money under this grant will be used to develop a p14-based drug delivery platform.

Read the entire release

Newsworthy: Anti-metastasis research highlighted in Nature Reviews Cancer

Nova Scotia, April 11, 2008 – In the story "Bringing up the rear", editor Kim Baumann reviews recently published metastasis research by Drs. Zijlstra and Lewis.

Read the news item

Newsworthy: Innovascreen's technology highlighted in SciBX

Nova Scotia, April 10, 2008 – Michael Haas's cover story discusses metastasis as a therapeutic target, highlighting Innovascreen's intravital imaging technology.

Read the news item

Innovascreen scientists identify new metastasis target

Nova Scotia, March 10, 2008 – A team of scientists, including Innovascreen’s founders Dr. Andries Zijlstra and Dr. John Lewis, have identified a human protein that may be a new target for future cancer therapies.

Read the news item

Innovascreen secures IRAP funding for ASET platform development

Nova Scotia, April 16, 2007 – Innovascreen announces today the approval of $232,328 in funding from the National Research Council of Canada’s Industrial Research Assistance Program (IRAP). The money will be used to develop a high throughput quantitative vasopermeation assay to complement our ASET platform.

Read the entire release

Innovascreen secures funding from ACOA for ASET platform development

Nova Scotia, August 15, 2006 – Innovascreen announces today the approval of $372,742 in funding from the Atlantic Canada Opportunities Agency (ACOA). The funds will be used to develop an integrated quantitative intravital imaging system.

Read the entire release

Newsworthy: Innovascreen featured in Business Review

Nova Scotia, February 20, 2006 – Heather Sawers of the Halifax Daily News introduces Innovascreen to the local business community in the article "Innovascreen gets cracking on cancer research".

Read the news article

Innovascreen signs first research contract

Nova Scotia, February 7, 2006 – Innovascreen announces today the signing of its first research contract with Peregrine Pharmaceuticals Inc, a research focused company located in Tustin, California.

Read the entire release

Innovascreen opens research facility

Nova Scotia, January 1, 2006 – Innovascreen today announced the opening of a Research facility located in the BioScience Enterprise Centre at 1721 Lower Water St. in Halifax, NS. The incubator is run by Innovacorp.

Read the entire release

Innovascreen Inc Founded with Preclinical Analytical Platform

Nova Scotia, August 30, 2005 – Innovascreen announces today the creation of an incorporated company to develop a powerful tool for the early preclinical development of therapeutic candidates. Built on an avian embryo model and utilizing a novel nanotechnology combined with powerful imaging capabilities, the system will allow screening of compound libraries and validation of lead candidates faster and better than traditional animal models, all at a lower cost. The system can capture the effect of a drug candidate on important cellular and disease characteristics in vivid images and 3D movies.

Read the entire release